Publications by authors named "Muhammed Ali Saldogan"
Expert Opin Drug Saf
April 2024
Article Synopsis
- The introduction of imatinib, the first tyrosine kinase inhibitor (TKI), has significantly improved survival rates for patients with chronic myeloid leukemia (CML), leading to concerns about the long-term safety of TKIs.
- This review compares the side effects of different TKIs used in treating CML and aims to create a safety profile based on extensive studies and real-life data collected from PubMed.
- Expert opinions suggest that while managing treatment side effects is crucial for maintaining effectiveness, modifications or alternative treatments may be necessary once treatment goals are met, highlighting the need for more research on dosing protocols and treatment-free remission safety.
